Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference

AUSTIN, Texas, May 27, 2020 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the company will present at the virtual Jefferies 2020 Healthcare Conference on Tuesday, June 2, 2020, at 4:30PM ET. Throughout that same day, Lumos Pharma management will also participate in one-on-one calls with investors. Please contact your Jefferies sales representative to schedule a one-on-one call with our management team. 
A live webcast of the presentation will be available on the Company’s website in the “Investors & Media” section under “Events and Presentations.” Listeners may also access the webcast through the following link: http://wsw.com/webcast/jeff126/lumo/. An archived edition of the presentation will be available on the Company’s website later in the day.About Lumos PharmaLumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.Investor & Media Contact:Lisa Miller
Lumos Pharma Investor Relations
512-648-3757
[email protected]
Source: Lumos Pharma, Inc.

Bay Street News

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search